Cardiovascular · Calcium Channel BlockerRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Diltiazem Hydrochloride ANDA216327

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Sciegen Pharmaceuticals15 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/9/2026, 12:00:15 AM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of Abbreviated New Drug Application (ANDA) approval for Diltiazem Hydrochloride to Sciegen Pharmaceuticals is significant as it introduces a new competitor in the cardiovascular space. This could disrupt existing market dynamics and necessitate strategic responses from established players to maintain their market share. Regulatory context from FDA (FDA AP — DILTIAZEM HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market dynamics and consider strategies for differentiation. The strongest clinical anchor is Bacterial Profile Changes During Different Sodium Hypochlorite Irrigation Regimens and Calcium Hydroxide Medicament in Root Canal Treatment (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular · Calcium Channel Blocker, 6 regulatory and 4 competitive items passed relevance filtering for Sciegen Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient (Merck) — sponsor/company relevance (merck). Secondary pressure from FDA Grants Approval for Phenylephrine Hydrochloride by Baxter Healthcare.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DILTIAZEM HYDROCHLORIDE (SUPPL) (FDA). Entity match (diltiazem hydrochloride); Regulatory pathway relevance (nda). The approval indicates a successful regulatory pathway for Sciegen, which may encourage further applications for similar products and influence future regulatory strategies.

Key Risks

Elevated medium regulatory exposure for Sciegen Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations) could weigh on Sciegen Pharmaceuticals through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of Sciegen's Diltiazem Hydrochloride may lead to price competition and affect the revenue streams of established brands in the cardiovascular market.
Portfolio teams should assess the impact of this approval on market dynamics and consider strategies for differentiation.

What Would Change This Assessment

This becomes more urgent if Monitor the launch timeline and market entry strategies of Sciegen Pharmaceuticals for Diltiazem Hydrochloride.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DILTIAZEM HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (diltiazem hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Bacterial Profile Changes During Different Sodium Hypochlorite Irrigation Regimens and Calcium Hydroxide Medicament in Root Canal Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluating New Radiation Techniques for Cardiovascular Imaging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Rehabilitation Assessment of Motor Function In Cerebral Palsy Using Explainable AI
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
FDA Grants Approval for Phenylephrine Hydrochloride by Baxter Healthcare
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants AP Status for Doxycycline Hyclate Supplement by Impax Labs
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approval Status Update for Losartan Potassium by Micro Labs
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Sciegen Pharmaceuticals
Diltiazem Hydrochloride
cardiovascular market
established brands

Commercial impact

medium

The entry of Sciegen's Diltiazem Hydrochloride may lead to price competition and affect the revenue streams of established brands in the cardiovascular market.

Regulatory impact

medium

The approval indicates a successful regulatory pathway for Sciegen, which may encourage further applications for similar products and influence future regulatory strategies.

What to watch

Monitor the launch timeline and market entry strategies of Sciegen Pharmaceuticals for Diltiazem Hydrochloride.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.